The life sciences sector is broad and captures a number of sub-sectors, including pharmaceutical, medical devices and biotech.
The report looks at a selection of our international corporate life sciences transactions to identify trends and developments, which can provide insightful intelligence for those operating in the sector and considering M&A activity, both domestically or internationally.
The report focuses on five key themes:
Due Diligence (DD)
Warranty and Indemnity (W&I) insurance
Trade v Private Equity
US v Rest of the World (RoW)
“Buyers and investors must pay close attention in conducting adequate regulatory due diligence, when evaluating targets in rapidly evolving environments.”
Marco de Morpurgo, Global Co-Chair and EU Regulatory Lead – Life Sciences
Please note, requests will be reviewed and approved at the discretion of DLA Piper. We cannot guarantee you will receive the report after submitting a request. Alternatively, please get in touch with your usual DLA Piper contact to request a copy.
DLA Piper is global law firm operating through various separate and distinct legal entities. For further information about these entities and DLA piper's structure, please refer the Legal Notices page of this website. All rights reserved. Attorney advertising.